OrbiMed’s VistaGen Therapeutics VTGN Stock Holding History

OrbiMed’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-45,200	Closed	-$29.9K	–	133
2025 Q4	$29.9K	Hold	45,200	–	–	﹤0.01%	107
2025 Q3	$160K	Buy	+45,200	New	+$135K	﹤0.01%	109

Other funds holding VTGN

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

OrbiMed's VTGN Position: Q2 2026 in Review

OrbiMed sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 3,060,000 shares — an estimated $1.75M sold.

OrbiMed first reported a position in VTGN in Q4 2020 and held it in 10 quarters. The position peaked at $45.6M in Q2 2021. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

OrbiMed reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
OrbiMed sold 3,060,000 VistaGen Therapeutics shares in Q2 2026, an estimated $1.75M.
OrbiMed first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 10 quarters.
OrbiMed's VistaGen Therapeutics position peaked at $45.6M in Q2 2021.
49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.